UroGen Pharma Ltd. (URGN)
Stock analysis · NASDAQ · Healthcare · Biotechnology
UroGen Pharma Ltd. (URGN) is a publicly traded company in the Healthcare sector. Latest price: $32.72. Market cap $1.60B. Trailing PE -16.53. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products…
Valuation
| P/E (TTM) | -16.53× |
|---|---|
| P/S (TTM) | 8.47× |
| P/B | -12.45× |
| P/FCF (TTM) | -10.05× |
| EV / EBITDA | -24.48× |
| EV / Sales | 9.09× |
| Earnings Yield | -5.92% |
| Free Cash Flow Yield | -9.95% |
Fundamentals
| Enterprise Value | $1.72B |
|---|---|
| Revenue (TTM) | $188.73M |
| Net Income (TTM) | -$94.73M |
| Free Cash Flow (TTM) | -$124.72M |
| Net Debt | $117.00M |
| Working Capital | $173.51M |
| Gross Margin | 90.85% |
| Operating Margin | -35.32% |
| Net Margin | -51.73% |
| Return on Equity | 81.78% |
| Return on Invested Capital | -34.41% |
Peers
Recent News
- UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tra…
- UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
- UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
- UroGen Pharma: An Emerging GARP Stock
- Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts
Related
Browse more tickers: sitemap